2148-2149 / 2351
R
Chemotherapy
Androgen deprivation
Primary endpoint: Progression-free survival
N= 152
A randomised phase II study to evaluate the efficacy and safety of
Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients
with recurrent and/or metastatic, androgen receptor (AR) expressing,
salivary gland cancer (SGCs)
EORTC 1206
Vermorken et al, NEJM, 2008